[Nature] Artificial intelligence (A.I.) is expected to significantly influence the practice of medicine and the delivery of healthcare in the near future. While there are only a handful of practical examples for its medical use with enough evidence, hype and attention around the topic are significant. There are so many papers, conference talks, misleading news […]
[BioWorld] Deals by Bayer AG’s “impact investment unit” called Leaps that build upon each other let the Leverkusen, Germany-based firm “basically renew [the company’s] technology platform” by tapping fresh sources, said Leaps head Jurgen Eckhardt. And the unit is casting nets widely.
[Korea Biomedical Review] GC said that it has partnered with Atomwise, a U.S. artificial intelligence-based drug development firm, to discover a new treatment candidate for hemophilia.